Skip to content
NeuroTechGuide

Nine-month-old Zhudong Technology raises RMB 464 million for implanted brain-computer interfaces

The Shanghai start-up has now raised about RMB 800 million in under three months, though no human implant has been reported.

2 min readImplantsFundingIndustry

Shanghai’s Zhudong Technology (主动科技) announced on November 4 that it has raised RMB 464 million, about $65 million, in an angel+ round. Gaorong Ventures, Guotou Xiandao and Shanghai Science and Technology Venture Capital co-led the round, and eight other investors and three existing shareholders also took part. It follows a RMB 330 million angel round announced on August 3, which brings the total to about RMB 800 million in under three months.

Chinese coverage describes both the round and the combined total as records for a Chinese brain-computer interface company at the angel stage, based on publicly disclosed deals. We could not check that claim independently.

What the company is building

Zhudong was founded in February 2026 and incubated by Shanghai’s Lingang Laboratory. It is developing implanted BCIs using its own flexible electrodes, chips, algorithms and system integration, with three product lines covering movement, vision and emotion.

Its lead product, Tianshu, is aimed at movement and speech impairments caused by stroke, spinal cord injury and ALS. The company also says a 1,024-channel implanted system received a type inspection report, a form of product testing, in November 2025. Reports do not say whether that system is Tianshu.

The money is meant to fund research, clinical translation and manufacturing, and the company says it is focused on Class III medical devices, China’s highest-risk category.

Why it matters

  • Scale at an early stage: the company has reported no human implant or trial, yet it has raised a sum comparable to later-stage rounds at Chinese BCI companies with patients already implanted.
  • A busy market: the round came days after Nanochap’s RMB 500 million round and NeuroXess’s RMB 700 million round. Gaorong Ventures took a leading role in both this round and Nanochap’s, according to Inside BCI.
  • Caveats: the details come from the company’s announcement and Chinese business media. No timeline for human studies has been disclosed. The US Treasury has separately proposed barring new US investment in Chinese BCI companies.

Learn more: Brain-computer interface · Channel count

Share:XLinkedInBlueskyEmail

More news